News
PolyPid Announces Participation in Upcoming Investor Conferences
PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today...
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results
The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET...
PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026
PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and...
PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors
Appointment Enhances PolyPid's Strategic, Commercial and Transaction Capabilities Ahead of D-PLEX New Drug Application SubmissionPETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma...
PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX Supporting NDA Submission
NDA to be Submitted on a Rolling Basis, Beginning Early 2026PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it...
PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025
Internationally recognized colorectal surgeon Steven D. Wexner, MD, FACS, FRCS, to discuss the clinical and economic burden of surgical site infections and the therapeutic potential of D-PLEX PETACH TIKVA, Israel, Nov. 25, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd....
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial...
PolyPid’s D-PLEX Wins BioTech Breakthrough Award for “Therapeutics Solution of the Year”
PolyPid's Lead Candidate Recognized for Addressing Critical Unmet Need in Surgical Site Infection Prevention Following Positive Phase 3 ResultsPETACH TIKVA, Israel, Nov. 06, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a...
PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025
PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and...
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
The Company will present the reported topline results from its phase 3 SHIELD II trial at one of the world's leading surgical conferencesPETACH TIKVA, Israel, Sept. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage...